AZ preps for US filing of kidney disease anaemia drug

AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia from chronic kidney disease (CKD), after supportive phase 3 results.

AZ's trio of new China R&D initiatives includes $1bn fund

AstraZeneca has announced three research initiatives in China including a potential $1 billion investment fund, in a country described by CEO Pascal Soriot as a “scientific powerhouse”.

Daiichi Sankyo takes Seattle Genetics to court as battle ove...

Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZen

Finally, AZ claims a win with Imfinzi/tremelimumab cancer co...

GSK's PARP drug Zejula approved in wider ovarian cancer popu...

The FDA has approved GlaxoSmithKline’s Zejula (niraparib) in a wider ovarian cancer indication, the first time a PARP class drug has been approved in a wider group of patients without the B

AZ’s new cancer drugs drive another stellar quarter